Tuesday, August 6th 2013
In the latest volume of the medical journal, Lasiers in Surgery and Medicine, three Harvard scientists concluded that Erchonia's research for its Verju low-level laser device has, "set the precedent on how aesthetic devices should be evaluated."
McKinney, TX (PRWEB) August 06, 2013
In the latest volume of the medical journal, Lasers in Surgery and Medicine, three Harvard scientists reviewed the merits of laser therapyfor body contouring that Erchonia's research for it's Verju low-level laser device has, "set the precedent on how aesthetic devices should be evaluated." One of the article's authors, Michael Hamblin, PhD., is recognized as the world's leading expert in low level laser therapy, making the praise all the more significant.
Verju was the first noninvasive aesthetic device to receive FDA market clearance in the U.S. for circumferential reduction of the waist, hips and thighs. Erchonia tested the Verju laser using a placebo-controlled, randomized, double blind, multisite clinical investigation evaluating 67 study participants. THe patients treated with the Verju laser experienced an average reduction of 4 inches across the waist, hips, and thighs in just two weeks.
The article praised Erchonia's clinical approach for Verju, noting, "The clinical trial absence of diet restrictions, exercise requirementsor any other adjunctive componets properly illustrated the clinical utility of the Verju and set the precedent on how aesthetic devices should be evaluated."
Steven Shanks, president of Erchonia comments, "Having an expert such as Dr. Hamblin recognize the quality of our research and the clinical utility of Erchonia's Verju laser is truly an honor. For a small medical device manufacturer like Erchonia, quality clinical research is pivotal for our overall success. Erchonia's research stands out in aesthetic medicine because more and more devices, such as Erchonia's competitors, such as fat freezinfg devices, are tested in non-randomized, non-controlled clinical trials."
This is not the first time an independent review recognized the clinical utility of Verju. An article published in Clinics in Plastic Surgery in 2011 stated, "Zerona is in a unique and beneficial category as it exemplifies a truly non-invasive approach, inducing slimming without the cell death or upregulation of inflammation."
For more information, please visit http://www.erchonia.com or http://www.myverju.com
Erchonia is the global leader in low level laser healthcare applications. Over the past 15 years, Erchonia has been conduction research and development with the world's leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven safe and effective through independent clinical trials. Currently thousands of Erchonia's lasers are used daily to reduce body fat, eliminate pain, and treat acne.
For additional information:
For the original version on PRWeb:
Read more at:
Read more at: